Table 4.

Comparative relapse and remission data with other reports following first dose of rituximab (RTX)

Study	Year	Diagnosis	Dose	No. patients	Duration of CD19+ B cell depletion	6 month EFS	1 yr. EFS	Median time to relapse*
Maxted et al	2017	FRNS or SDNS	Variable: 375 mg/m2 to 1.5 g/m2	59	Median depletion 10 months	84%	46%	11 months
			1 × 375 mg/m2	40	Median depletion 10 months	81%	38%	11 months
Niu et al	2016	SDNS	Single dose 375 mg/m2	19	Mean depletion time 3 months	74%	63%	5 months
Ravani et al	2015	SDNS	Single dose 375 mg/m2	15	Mean depletion 6 months	93%	66%	18 months (between RTX treatments)
Iijima et al	2014	FRNS or SDNS	4 doses 375 mg/m2	20	Median depletion lasted 5 months	–	15%	9 months
Tellier et al	2013	SDNS	1–4 doses 375 mg/m2 (10 patients received 4)	18	–	–	–	13 months
Sellier-Leclerc et al	2012	SDNS	1–4 doses 375 mg/m2 (15 patients received 4)	30	Median depletion 8 months	–	–	–
Ravani et al	2011	SDNS	1–2 doses of 375 mg/m2	27	–	50%	25%	–
Sinha et al	2015	SDNS	1–4 doses of 375 mg/m2	101	–	92%	58%	16 months
Hogan et al	2018	SDNS	1 dose of 375 mg/m2	35	Median depletion 5 months	–	59%	–

EFS event-free survival, SDNS steroid-dependent nephrotic syndrome, FRNS frequently relapsing nephrotic syndrome

*Excludes patients receiving prophylactic dosing and those with no subsequent relapse